Login / Signup

PEC-PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent.

Justine GantzerMaud ToulmondeFrançois SeveracAli N ChamseddineCéline Charon-BarraCharles VinsonAlice HervieuAgathe BourgmayerFrançois BertucciThomas RyckewaertThibaud ValentinNelly FirminLoïc ChaigneauEmmanuelle BompasPhilippe FollanaNathalie Rioux-LeclercqPauline Soibinet-OudotLaurence BozecFrançois Le LoarerNoëlle WeingertnerChristine ChevreauFlorence DuffaudJean Yves BlayJean-Emmanuel KurtzPatrick SchöffskiMehdi BrahmiGabriel G Malouf
Published in: Cancer (2024)
The PEC-PRO score reliably predicts the risk of postoperative recurrence in patients with localized PEComa. It has the potential to improve follow-up strategies but requires validation in a prospective trial.
Keyphrases
  • anti inflammatory
  • single cell
  • clinical trial
  • patients undergoing
  • cell therapy
  • study protocol
  • phase iii
  • phase ii
  • stem cells
  • randomized controlled trial
  • prognostic factors
  • human health
  • risk assessment
  • open label